| Bioactivity | CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for JNK1 over JNK2 in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis[1][2]. | |||||||||
| Invitro | CC-90001 blocks LPS-induced c-jun phosphorylation with an EC50 of 480 nM in cellular assays[1].CC-90001 is 12.9-fold more potent for JNK1 inhibition than JNK2 using JNK1 and JNK2 knockout fibroblasts[1]. | |||||||||
| In Vivo | CC-90001 (3 mg/kg b.i.d.) reduces the development of fibrosis, as evidenced by a 48% reduction in collagen and a 53% reduction in α-smooth muscle actin (α-SMA) in a steatohepatitis model[1].CC-90001 decreases multiple measures of lung collagen and reduces disease induced increases in α-SMA to nearly baseline levels in a house dust mite model of lung fibrosis[1]. | |||||||||
| Name | CC-90001 | |||||||||
| CAS | 1403859-14-2 | |||||||||
| Formula | C16H27N5O2 | |||||||||
| Molar Mass | 321.42 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Bennett B, et, al. CC-90001, a Second Generation Jun N-Terminal Kinase (JNK) Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 2017; 195:A5409. [2]. Kolb M, et, al. Therapeutic targets in idiopathic pulmonary fibrosis. Respir Med. 2017 Oct;131:49-57. |
CC-90001
CAS: 1403859-14-2 F: C16H27N5O2 W: 321.42
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold s
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.